Piramal Pharma and IntoCell Join Forces to Enhance Bioconjugate Platforms and Capabilities

Enhancing Bioconjugate Capabilities: The Piramal and IntoCell Partnership

In a significant development within the pharmaceutical and biotechnology industry, Piramal Pharma Solutions has officially formed a strategic partnership with IntoCell Inc. This collaboration aims to broaden Piramal's existing capabilities in bioconjugate technology and payload-linker development, solidifying its competitive edge in the market.

A Collaborative Approach to Innovation

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), recently announced the signing of a memorandum of understanding with the esteemed South Korean biotech firm, IntoCell. This partnership is poised to leverage IntoCell's proprietary drug-linker technologies along with Piramal's expansive expertise in antibody-drug conjugates (ADCs) to enhance the overall innovation in this field.

As part of the agreement, IntoCell will explore licensing options for its proprietary linker technologies with Piramal's clients. In return, Piramal will offer comprehensive research, development, and manufacturing services related to bioconjugates, including ADCs. This non-exclusive and non-binding agreement marks a significant step forward in both companies' missions to advance drug development solutions.

Strengthening Existing Capabilities

With this partnership, Piramal Pharma enhances its payload-linker platform, which is crucial for the efficacy of ADCs. Among the various technologies included in this collaboration are the OHPAS linker, OHPAS payload based on duocarmycin, and sophisticated payloads like iso-Nexatecan and GGFG. This expanded range will ultimately result in shorter development timelines for bioconjugates, thereby improving service quality and competitiveness in this specialized market.

Peter DeYoung, CEO of Piramal Global Pharma, expressed optimism regarding the partnership, stating, "By combining IntoCell's revolutionary linker technologies with our extensive expertise in bioconjugates, we are positioning ourselves as the optimal partner for clients innovating in this critical segment. This collaboration significantly enhances our capabilities and enables us to redefine the future of ADCs for better patient outcomes worldwide."

Insights from IntoCell

Tae Kyo Park, CEO of IntoCell, also shared his enthusiasm for the partnership, noting that the collaboration would ensure mutual success between both companies by harnessing their respective expertise. This sentiment reflects the collaborative spirit of both organizations in their quest to innovate within the bioconjugate space.

A Broader Vision for Drug Development

The partnership not only aims to enhance the capabilities of Piramal in delivering bioconjugate solutions but also synergizes industry-leading approaches for expediting ADC development. This aligns with Piramal’s ADCelerate™ strategy, which focuses on faster and integrated development and manufacturing processes for ADCs. Combining resources from both companies provides a streamlined path from concept to clinical application, ultimately benefiting both manufacturers and patients alike.

The collaboration represents a forward-thinking approach to biotechnology, with the potential for innovative advances in ADC technology that could revolutionize treatment methodologies across various therapeutic areas.

About the Companies Involved

Piramal Pharma Solutions

Piramal Pharma Solutions provides comprehensive drug development and manufacturing solutions across the pharmaceutical product lifecycle. With a robust network of facilities across the Americas, Europe, and Asia, the organization supports a wide range of client needs, including drug discovery, process development, clinical trial supplies, and commercial formulation of APIs and finished pharmaceutical products. Their specialization encompasses potent active pharmaceutical ingredients and antibody-drug conjugates, alongside services related to biological products like vaccines and gene therapies.

About IntoCell

IntoCell Inc. is a leading biotechnology firm listed on KOSDAQ, focusing on innovative linker-payload technologies that enhance stability, solubility, and controlled release of ADC payloads. Their proprietary technologies, including OPHAS linker technology, are integral to advancing the next generation of antibody-drug conjugates, positioning them as leaders in innovative drug delivery systems.

In conclusion, the partnership between Piramal Pharma Solutions and IntoCell signifies a momentous shift towards enhanced bioconjugate solutions, promising to foster greater advancements in therapeutic developments to provide improved outcomes for patients around the globe.